A neutral, evidence-rated side-by-side of Tamoxifen and Clomifene. Figures are typical reference values, not recommendations.
| Tamoxifen | Clomifene | |
|---|---|---|
| Type | Ancillary | Ancillary |
| Evidence level | Well established | Well established |
| Primary class | Ancillary | Ancillary |
| Half-life | ~5-7 days (active metabolites longer) | ~5-7 days (zuclomiphene isomer much longer, weeks) |
| Typical dose | 10–20 mg/day | 25–50 mg/day |
| Documented effects | 2 | 2 |
| Documented side effects | 3 | 3 |
Tamoxifen is a selective oestrogen receptor modulator (SERM) with decades of oncology trial data. It antagonises oestrogen at breast tissue (used to prevent and treat gynaecomastia) while acting as an oestrogen agonist at the hypothalamus/pituitary, raising LH, FSH and endogenous testosterone — which makes it a mainstay of post-cycle therapy (PCT).
Full Tamoxifen page →Clomifene (clomiphene) is a SERM, a mixture of two isomers (enclomiphene and zuclomiphene). Like tamoxifen it blocks oestrogen feedback at the pituitary to raise LH, FSH and testosterone, and it is widely used in PCT and for male hypogonadism/fertility. Its distinctive drawback is oestrogenic-agonist visual side effects — blurring, floaters and flashes — driven largely by the long-lived zuclomiphene isomer.
Full Clomifene page →